Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate
Identifieur interne : 001695 ( Istex/Checkpoint ); précédent : 001694; suivant : 001696Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate
Auteurs : Anne-Marie Maurer [France] ; Zhong Chao Han [France] ; Didier Dhermy [France] ; Jean Briere [France]Source :
- The Journal of Laboratory and Clinical Medicine [ 0022-2143 ] ; 1996.
Abstract
We have previously reported that platelet factor 4 (PF4) inhibits human erythroleukemic (HEL) cell growth in a dose-dependent fashion in vitro and that PF4 binds to HEL cells in a specific, saturable, and concentration-dependent manner. In this article we demonstrate that the binding of PF4 on HEL cells and its inhibitiroy effect on HEL cell growth were mediated by heparan sulfate. We found that binding of iodine 125-labeled PF4 to HEL cells was inhibited by heparin, heparan sulfate, and dermatan sulfate and to a smaller extent by chondroitin sulfate. Ninety percent of 125I-labeled PF4 bound to HEL cells was released by cells after exposure to heparin and heparan sulfate. Treatment of cells with heparitinase and heparinase induced a decrease in the binding of 125I-labeled PF4 to cells. Binding of 125I-labeled PF4 was partially inhibited by the presence of increasing concentrations of protamine sulfate and basic fibroblast growth factor. To test whether PF4 bound to cell surface proteoglycans, proteoglycan synthesis was inhibited by using 4-methylumbelliferyl-β-D-xyloside. The binding of 125I-labeled PF4 on treated cells was decreased, and xyloside treatment of cells abrogated the biologic activity of PF4 in a plasma clot culture system. The inhibitory effect of PF4 was retained in a serum-free agar culture system, which indicates that the binding of PF4 to HEL cells induces cell growth inhibition in a direct fashion. Taken together, these findings suggest that PF4 directly acts on HEL cell growth by fixation on heparan sulfate proteoglycans on the HEL cell surface.
Url:
DOI: 10.1016/S0022-2143(96)90186-9
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:BE8E1B2D601E90039E3349EB6C2A299D7FD5DD5ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate</title><author><name sortKey="Maurer, Anne Marie" sort="Maurer, Anne Marie" uniqKey="Maurer A" first="Anne-Marie" last="Maurer">Anne-Marie Maurer</name></author><author><name sortKey="Han, Zhong Chao" sort="Han, Zhong Chao" uniqKey="Han Z" first="Zhong Chao" last="Han">Zhong Chao Han</name></author><author><name sortKey="Dhermy, Didier" sort="Dhermy, Didier" uniqKey="Dhermy D" first="Didier" last="Dhermy">Didier Dhermy</name></author><author><name sortKey="Briere, Jean" sort="Briere, Jean" uniqKey="Briere J" first="Jean" last="Briere">Jean Briere</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BE8E1B2D601E90039E3349EB6C2A299D7FD5DD5A</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/S0022-2143(96)90186-9</idno><idno type="url">https://api.istex.fr/document/BE8E1B2D601E90039E3349EB6C2A299D7FD5DD5A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C44</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C44</idno><idno type="wicri:Area/Istex/Curation">001C42</idno><idno type="wicri:Area/Istex/Checkpoint">001695</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001695</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate</title><author><name sortKey="Maurer, Anne Marie" sort="Maurer, Anne Marie" uniqKey="Maurer A" first="Anne-Marie" last="Maurer">Anne-Marie Maurer</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 409, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service d'hématologie clinique, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Han, Zhong Chao" sort="Han, Zhong Chao" uniqKey="Han Z" first="Zhong Chao" last="Han">Zhong Chao Han</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 409, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service d'hématologie clinique, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Dhermy, Didier" sort="Dhermy, Didier" uniqKey="Dhermy D" first="Didier" last="Dhermy">Didier Dhermy</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 409, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service d'hématologie clinique, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Briere, Jean" sort="Briere, Jean" uniqKey="Briere J" first="Jean" last="Briere">Jean Briere</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Reprint requests: Professor Jean Brière, Service d'hématologie clinique, Hôpital Beaujon, 100, Boulevard du Général Leclerc, 92118 Clichy Cédex</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Clichy Cédex</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 409, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service d'hématologie clinique, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Laboratory and Clinical Medicine</title><title level="j" type="abbrev">YMLC</title><idno type="ISSN">0022-2143</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">127</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="382">382</biblScope><biblScope unit="page" to="390">390</biblScope></imprint><idno type="ISSN">0022-2143</idno></series><idno type="istex">BE8E1B2D601E90039E3349EB6C2A299D7FD5DD5A</idno><idno type="DOI">10.1016/S0022-2143(96)90186-9</idno><idno type="PII">S0022-2143(96)90186-9</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-2143</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have previously reported that platelet factor 4 (PF4) inhibits human erythroleukemic (HEL) cell growth in a dose-dependent fashion in vitro and that PF4 binds to HEL cells in a specific, saturable, and concentration-dependent manner. In this article we demonstrate that the binding of PF4 on HEL cells and its inhibitiroy effect on HEL cell growth were mediated by heparan sulfate. We found that binding of iodine 125-labeled PF4 to HEL cells was inhibited by heparin, heparan sulfate, and dermatan sulfate and to a smaller extent by chondroitin sulfate. Ninety percent of 125I-labeled PF4 bound to HEL cells was released by cells after exposure to heparin and heparan sulfate. Treatment of cells with heparitinase and heparinase induced a decrease in the binding of 125I-labeled PF4 to cells. Binding of 125I-labeled PF4 was partially inhibited by the presence of increasing concentrations of protamine sulfate and basic fibroblast growth factor. To test whether PF4 bound to cell surface proteoglycans, proteoglycan synthesis was inhibited by using 4-methylumbelliferyl-β-D-xyloside. The binding of 125I-labeled PF4 on treated cells was decreased, and xyloside treatment of cells abrogated the biologic activity of PF4 in a plasma clot culture system. The inhibitory effect of PF4 was retained in a serum-free agar culture system, which indicates that the binding of PF4 to HEL cells induces cell growth inhibition in a direct fashion. Taken together, these findings suggest that PF4 directly acts on HEL cell growth by fixation on heparan sulfate proteoglycans on the HEL cell surface.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Clichy Cédex</li><li>Paris</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Maurer, Anne Marie" sort="Maurer, Anne Marie" uniqKey="Maurer A" first="Anne-Marie" last="Maurer">Anne-Marie Maurer</name></noRegion><name sortKey="Briere, Jean" sort="Briere, Jean" uniqKey="Briere J" first="Jean" last="Briere">Jean Briere</name><name sortKey="Briere, Jean" sort="Briere, Jean" uniqKey="Briere J" first="Jean" last="Briere">Jean Briere</name><name sortKey="Briere, Jean" sort="Briere, Jean" uniqKey="Briere J" first="Jean" last="Briere">Jean Briere</name><name sortKey="Briere, Jean" sort="Briere, Jean" uniqKey="Briere J" first="Jean" last="Briere">Jean Briere</name><name sortKey="Dhermy, Didier" sort="Dhermy, Didier" uniqKey="Dhermy D" first="Didier" last="Dhermy">Didier Dhermy</name><name sortKey="Dhermy, Didier" sort="Dhermy, Didier" uniqKey="Dhermy D" first="Didier" last="Dhermy">Didier Dhermy</name><name sortKey="Dhermy, Didier" sort="Dhermy, Didier" uniqKey="Dhermy D" first="Didier" last="Dhermy">Didier Dhermy</name><name sortKey="Han, Zhong Chao" sort="Han, Zhong Chao" uniqKey="Han Z" first="Zhong Chao" last="Han">Zhong Chao Han</name><name sortKey="Han, Zhong Chao" sort="Han, Zhong Chao" uniqKey="Han Z" first="Zhong Chao" last="Han">Zhong Chao Han</name><name sortKey="Han, Zhong Chao" sort="Han, Zhong Chao" uniqKey="Han Z" first="Zhong Chao" last="Han">Zhong Chao Han</name><name sortKey="Maurer, Anne Marie" sort="Maurer, Anne Marie" uniqKey="Maurer A" first="Anne-Marie" last="Maurer">Anne-Marie Maurer</name><name sortKey="Maurer, Anne Marie" sort="Maurer, Anne Marie" uniqKey="Maurer A" first="Anne-Marie" last="Maurer">Anne-Marie Maurer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001695 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001695 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:BE8E1B2D601E90039E3349EB6C2A299D7FD5DD5A
|texte= Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate
}}
| This area was generated with Dilib version V0.6.29. |  |